Literature DB >> 25917669

Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis: Implications for Targeted Therapy.

James J Jaber1, Lauren Murrill2, Joseph I Clark3, Jonas T Johnson4, Paul J Feustel5, Vikas Mehta6.   

Abstract

OBJECTIVE: Historically, head and neck squamous cell carcinoma (HNSCC) has been earmarked a lymphatic malignancy. Recently, this has been called into question. Our study aims to (1) illustrate the robust differences in distant metastases between p16+ and p16- oropharyngeal squamous cell carcinoma (OPSCC) and (2) provide support that p16+ OPSCC has a predilection toward vasculature invasion and hematogenous spread. STUDY
DESIGN: Multi-institutional, case series with chart review.
SETTING: Four academic institutions. SUBJECTS AND METHODS: Within a group of 1113 patients with primary OPSCC who received treatment between 1979 and 2013, those who developed distant metastasis (DM) were divided into 2 cohorts based on p16 status. Intergroup and intragroup univariate analysis was performed as well as descriptive analysis of end-organ sites.
RESULTS: Of the 1058 patients included, 89 developed DM. Thirty were p16- and 59 were p16+. Of the p16- patients with DM, only 10% had disseminated disease (distant metastases at ≥2 sites) compared with 74% of p16+ patients. Distant disease in p16+ patients included brain, abdomen, and a distinct pattern of pulmonary metastases.
CONCLUSION: Our large, multi-institutional study supports published reports that p16+ OPSCC metastasizes with a unique phenotype that is hematogenous and widely disseminated with atypical end-organ sites. Our data suggest that p16+ OPSCC has a predilection toward active vasculature invasion as evidenced by the results and illustrative radiologic and pathohistologic examples. These findings may have implications for future targeted therapy when treating p16+ OPSCC. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2015.

Entities:  

Keywords:  distant metastasis; hematogenous spread; human papillomavirus; metastases; oropharyngeal squamous cell carcinoma; p16+; p16-dependent

Mesh:

Year:  2015        PMID: 25917669     DOI: 10.1177/0194599815581836

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  4 in total

1.  The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting.

Authors:  Stephen F Hall; Rebecca J Griffiths; Brian O'Sullivan; Fei-Fei Liu
Journal:  Head Neck       Date:  2019-02-04       Impact factor: 3.147

2.  Detection of Human Papillomavirus Integration in Brain Metastases from Oropharyngeal Tumors by Targeted Sequencing.

Authors:  Brian McEllin; Brian C Searle; Lisa DePledge; George Sun; Charles Cobbs; Mohsen Karimi
Journal:  Viruses       Date:  2021-08-03       Impact factor: 5.048

3.  Treatment failure patterns are similar between p16- and p16+ oropharyngeal squamous cell carcinomas.

Authors:  Chelsea S Hamill; Richard Grant Muller; Kate Clancy; Brandon Vu; Shanying Gui; Jason Eric Thuener; Jay Wasman; Shawn Li; Nicole Fowler; Rod Rezaee; Pierre Lavertu; Theodoros N Teknos; Quintin Pan; Wendi Quinn O'Neill
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-06-01

4.  Prognostic Impact of Metastatic Site and Pattern in Patients with Metastatic Head and Neck Cancer.

Authors:  Craig A Bollig; Christopher I Newberry; Tabitha L I Galloway; Robert P Zitsch; Elyse K Hanly; Vivian L Zhu; Nitin Pagedar; Rohit Nallani; Andres M Bur; William C Spanos; Jeffrey B Jorgensen
Journal:  Laryngoscope       Date:  2020-10-24       Impact factor: 3.325

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.